PRINCETON, N.J., Jan. 20, 2011 /PRNewswire/ -- For a third consecutive year, Novo Nordisk, a global healthcare company focusing on diabetes care, has been named to FORTUNE Magazine's prestigious "100 Best Companies to Work For" list for 2011. Novo Nordisk is ranked 47th in the overall list and is only one of three pharmaceutical/biotechnology companies so honored. (Logo: http://photos.prnewswire.com/prnh/20020404/NVOLOGO ) "We are extremely honored to be recognized by FORTUNE as one of the '100 Best Companies to Work For'," said Jerzy Gruhn, president of Novo Nordisk Inc. "Everyone in Novo Nordisk has a personal interest in defeating diabetes and supporting patients with hemophilia and other serious conditions. We are so glad to see these efforts noticed for three years in a row." To pick the "100 Best Companies to Work For," FORTUNE partners with the Great Place to Work Institute to conduct the most extensive employee survey in corporate America. Three hundred eleven companies participated in this year's survey. Two-thirds of a company's score is based on the results of the Institute's Trust Index survey, which is sent to a random sample of employees from each company. The survey asks questions related to their attitudes about management's credibility, job satisfaction, and camaraderie. The other third of the scoring is based on the company's responses to the Institute's Culture Audit, which includes detailed questions about pay and benefit programs and a series of open-ended questions about hiring practices, internal communications, training, recognition programs and diversity efforts. "At Novo Nordisk, we're all active stewards of our corporate culture. It's that engagement that allows us to develop and provide medicines of value for people with diabetes and hemophilia," said Jeff Frazier, Vice President of Human Resources. "I appreciate that our efforts to reward our employees for all their great work is recognized by FORTUNE and others in our industry." About Novo Nordisk Novo Nordisk is a healthcare company with an 87-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women.